BR112016007328A2 - composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas - Google Patents
composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmasInfo
- Publication number
- BR112016007328A2 BR112016007328A2 BR112016007328A BR112016007328A BR112016007328A2 BR 112016007328 A2 BR112016007328 A2 BR 112016007328A2 BR 112016007328 A BR112016007328 A BR 112016007328A BR 112016007328 A BR112016007328 A BR 112016007328A BR 112016007328 A2 BR112016007328 A2 BR 112016007328A2
- Authority
- BR
- Brazil
- Prior art keywords
- epinephrine
- methods
- compositions
- based ophthalmic
- ophthalmic compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/02—Internal fittings
- B65D25/04—Partitions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886269P | 2013-10-03 | 2013-10-03 | |
| US201361892872P | 2013-10-18 | 2013-10-18 | |
| US201461947778P | 2014-03-04 | 2014-03-04 | |
| PCT/US2014/059077 WO2015051264A1 (en) | 2013-10-03 | 2014-10-03 | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016007328A2 true BR112016007328A2 (pt) | 2017-08-01 |
Family
ID=52779188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016007328A BR112016007328A2 (pt) | 2013-10-03 | 2014-10-03 | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10993921B2 (enExample) |
| EP (1) | EP3052095A4 (enExample) |
| JP (2) | JP2016532723A (enExample) |
| KR (1) | KR20160070077A (enExample) |
| AU (2) | AU2014329412B2 (enExample) |
| BR (1) | BR112016007328A2 (enExample) |
| CA (1) | CA2925008A1 (enExample) |
| IL (1) | IL244687A0 (enExample) |
| MX (1) | MX2016004257A (enExample) |
| WO (1) | WO2015051264A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12702651B2 (en) | 2013-10-03 | 2026-08-11 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| BR112016007328A2 (pt) * | 2013-10-03 | 2017-08-01 | Imprimis Pharmaceuticals Inc | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
| TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| WO2018039420A1 (en) * | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| EP3687475A4 (en) * | 2017-09-26 | 2021-07-28 | YS Pharmtech | STABILIZATION OF EPINEPHRIN FORMULATIONS |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| CA3093725C (en) | 2018-03-23 | 2021-08-24 | Nevakar Inc. | Epinephrine compositions and containers |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US20230277694A1 (en) * | 2022-03-04 | 2023-09-07 | Harrow Ip, Llc | Ophthalmic dye composition and method for administering same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US4590210A (en) * | 1979-03-09 | 1986-05-20 | Langham Maurice E | Compositions for treatment of ocular hypertension |
| US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| CA2002643A1 (en) * | 1988-11-09 | 1990-05-09 | Maryjane Helenek | Antioxidant-free epinephrine solution for ophthalmic use |
| NL9102148A (nl) * | 1991-12-20 | 1993-07-16 | Dsm Nv | Copolymeer van lacton en carbonaat en werkwijze voor het verkrijgen ervan. |
| WO1994008602A1 (en) * | 1992-10-21 | 1994-04-28 | Alcon Laboratories, Inc. | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery |
| US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
| US5709852A (en) | 1995-12-05 | 1998-01-20 | Basf Corporation | Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends |
| WO1998003641A1 (en) | 1996-07-23 | 1998-01-29 | Crandall Wilson T | Transdermal transport of molecules |
| FR2779061B1 (fr) * | 1998-04-14 | 2004-08-20 | Pharmatop | Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant |
| DE19859427A1 (de) | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
| WO2000048662A1 (en) * | 1999-02-16 | 2000-08-24 | Prismedical Corporation | Single dose delivery device |
| EP1326642A2 (en) * | 2000-09-29 | 2003-07-16 | Board of Trustees operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
| FR2833493B1 (fr) * | 2001-12-18 | 2005-09-23 | Ioltechnologie Production | Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble |
| EP1531794B1 (en) * | 2002-06-28 | 2017-05-10 | Civitas Therapeutics, Inc. | Inhalable epinephrine |
| ES2397574T3 (es) | 2002-07-30 | 2013-03-08 | Omeros Corporation | Procedimiento y soluciones de irrigación oftalmológica |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US20050176823A1 (en) | 2004-02-10 | 2005-08-11 | Diaz Robert L. | Intra-operative procedure for post-operative pain control |
| FR2882930B1 (fr) * | 2005-03-09 | 2009-03-27 | Walid Katib | Nouvelles compositions ophtalmologiques et leur mode d'utilisation |
| DE102005038368A1 (de) | 2005-08-13 | 2007-02-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Doppelkammer-Behälter zur Lyophilisation, Verfahren zu dessen Befüllung und dessen Verwendung |
| US20070196324A1 (en) | 2006-02-01 | 2007-08-23 | Keefe Candace R | Cellulite skin treatment methods and compositions |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US20080269347A1 (en) * | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| US20090017120A1 (en) | 2007-03-23 | 2009-01-15 | Humco Holding Group, Inc. | Phase stable lecithin organogel composition |
| US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| EP2711001A3 (en) | 2008-11-14 | 2014-07-02 | Archer-Daniels-Midland Company | Organogel compositions and processes for producing |
| CN101444481A (zh) | 2009-01-06 | 2009-06-03 | 河北科技大学 | 不含抑菌剂的托吡卡胺滴眼液及其制备方法 |
| WO2010139752A2 (en) * | 2009-06-04 | 2010-12-09 | Alk Ag | Stabilised composition comprising at least one adrenergic compound |
| WO2011156803A2 (en) | 2010-06-11 | 2011-12-15 | Transdel Pharmaceuticals, Inc. | Anti-cellulite composition and method of treating cellulite |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| KR20140112825A (ko) | 2013-03-14 | 2014-09-24 | 삼성전자주식회사 | 전자 장치의 전자 결제 방법 및 장치 |
| CA2915814A1 (en) | 2013-06-18 | 2014-12-24 | Harrow Ip, Llc | Local use of pentoxifylline to treat peyronie's disease |
| WO2015006299A1 (en) | 2013-07-08 | 2015-01-15 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical formulations of tranexamic acid and their use |
| BR112016007328A2 (pt) | 2013-10-03 | 2017-08-01 | Imprimis Pharmaceuticals Inc | composições oftálmicas baseadas em epinefrina para administração intraocular e métodos para fabricar as mesmas |
| WO2018039420A1 (en) | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
-
2014
- 2014-10-03 BR BR112016007328A patent/BR112016007328A2/pt not_active IP Right Cessation
- 2014-10-03 US US14/506,120 patent/US10993921B2/en active Active
- 2014-10-03 JP JP2016546889A patent/JP2016532723A/ja active Pending
- 2014-10-03 AU AU2014329412A patent/AU2014329412B2/en active Active
- 2014-10-03 CA CA2925008A patent/CA2925008A1/en not_active Abandoned
- 2014-10-03 KR KR1020167009782A patent/KR20160070077A/ko not_active Ceased
- 2014-10-03 WO PCT/US2014/059077 patent/WO2015051264A1/en not_active Ceased
- 2014-10-03 EP EP14851190.0A patent/EP3052095A4/en not_active Withdrawn
- 2014-10-03 MX MX2016004257A patent/MX2016004257A/es unknown
-
2016
- 2016-03-21 IL IL244687A patent/IL244687A0/en unknown
- 2016-08-19 US US15/241,958 patent/US20160354308A1/en not_active Abandoned
- 2016-08-25 US US15/247,524 patent/US11045432B2/en active Active
-
2019
- 2019-05-08 JP JP2019088480A patent/JP2019142964A/ja active Pending
-
2020
- 2020-05-08 AU AU2020203044A patent/AU2020203044A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,023 patent/US20210275471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20170049721A1 (en) | 2017-02-23 |
| EP3052095A4 (en) | 2017-07-05 |
| US11045432B2 (en) | 2021-06-29 |
| US20210275471A1 (en) | 2021-09-09 |
| EP3052095A1 (en) | 2016-08-10 |
| KR20160070077A (ko) | 2016-06-17 |
| MX2016004257A (es) | 2016-08-17 |
| CA2925008A1 (en) | 2015-04-09 |
| US10993921B2 (en) | 2021-05-04 |
| US20150119440A1 (en) | 2015-04-30 |
| JP2016532723A (ja) | 2016-10-20 |
| AU2014329412A1 (en) | 2016-05-05 |
| JP2019142964A (ja) | 2019-08-29 |
| WO2015051264A8 (en) | 2016-04-07 |
| IL244687A0 (en) | 2016-04-21 |
| AU2014329412B2 (en) | 2020-02-27 |
| WO2015051264A1 (en) | 2015-04-09 |
| AU2020203044A1 (en) | 2020-05-28 |
| US20160354308A1 (en) | 2016-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016004257A (es) | Composiciones oftalmicas basadas en epinefrina para la administracion intraocular y metodos para su frabricacion. | |
| CY1124998T1 (el) | Ετεροκυκλικες ενωσεις και χρήσεις αυτων | |
| BR112018005349A2 (pt) | preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112015022191A8 (pt) | compostos heteroarila e usos dos mesmos | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
| BR112017008157A2 (pt) | polipeptídeos de fgf-21 modificados e usos dos mesmos | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| EA201591661A1 (ru) | Пептиды и композиции для лечения повреждений суставов | |
| BR112015028152A2 (pt) | inibidores de acc e usos dos mesmos | |
| WO2014153009A3 (en) | Thiosaccharide mucolytic agents | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| BR112017015580A2 (pt) | composição de limpeza para lavagem de louça, e, método para formar uma composição de limpeza para lavagem de louça | |
| EA202090683A3 (ru) | Способы и композиции для лечения рака | |
| BR112016001544A8 (pt) | composições farmacêuticas para a administração intraocular que compreende um agente antibacteriano e um agente anti-inflamatório | |
| TR201815173T4 (tr) | Peptit bileşimleri. | |
| BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
| PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition | |
| EA201501054A1 (ru) | Лечение миопатий и нейродегенеративных заболеваний, связанных с агрегацией белков, путём парентерального введения трегалозы | |
| EA201791716A1 (ru) | Фармацевтический состав | |
| BR112015031417A8 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| NZ735777A (en) | Methods and compositions to inhibit symptoms associated with veisalgia | |
| BR112017000898A2 (pt) | oritavancina de alta pureza e método de produção da mesma | |
| BR112018069782A2 (pt) | composição farmacêutica de dapagliflozina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: HARROW IP, LLC (US) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2690 DE 26-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |